Results 271 to 280 of about 243,764 (341)

Novel Histopathologic Features of Diffuse Blue‐Gray Hyperpigmentation Associated With Kratom Use: A Case Report and Literature Review

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Drug‐induced hyperpigmentation accounts for 10%–20% of acquired pigmentary disorders and can be misdiagnosed for other causes such as melasma, post inflammatory changes, or heavy metal deposition. Kratom (Mitragyna speciosa), a Southeast Asian plant with an opioid‐like profile, has been increasingly used in the United States for ...
Rita Kamoua, Kristen Paradine, Craig A. Rohan, Mary McDaniel, Diane Perkins   +4 more
wiley   +1 more source

Antipsychotics and Amotivation

Neuropsychopharmacology, 2015
G. Fervaha*, H. Takeuchi, Jimmy Lee, G. Foussias, P. Fletcher, O. Agid, G. Remington   +6 more
semanticscholar   +1 more source

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou, Huilin Tang, Bingyu Zhang, Dazheng Zhang, Yiwen Lu, Lu Li, Jiajie Chen, Yong Chen, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Antipsychotic discontinuation in schizophrenia: rational or reckless? [PDF]

Schizophrenia (Heidelb)
Zipursky RB, Agid O, Remington G.
europepmc   +1 more source

Antipsychotic drug use in Canadian long-term care facilities: prevalence, and patterns following resident relocation

, 2005
Brad Hagen, Chris Armstrong Esther, Roland Ikuta, Robert J. Williams, Carole-Lynne Le Navenec, Morgan Aho   +5 more
openalex   +1 more source

Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Objective This observational study examined changes in mental health and wellbeing after 4‐months liraglutide 3.0 mg treatment in patients with obesity and explored associations with weight loss. Methods We included 98 patients with obesity treated with liraglutide 3.0 mg.
Susanne Kuckuck, Nina van Gerwen, Johanneke E. Oosterman, Mesut Savas, Maryam Kavousi, Brenda W. J. H. Penninx, Mariëtte R. Boon, Elisabeth F.C. van Rossum   +7 more
wiley   +1 more source

Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain

, 2018
Frederik Vandenberghe, Alexandra Najar-Giroud, Laurent Holzer, Philippe Conus, Chin B. Eap, Anne‐Emmanuelle Ambresin   +5 more
openalex   +2 more sources

Association of Atypical Antipsychotics With Lipid Abnormalities in Adult Patients With Schizophrenia: A Scoping Review. [PDF]

Neuropsychopharmacol Rep
Abavana V, Sadiq S.
europepmc   +1 more source

D1/D5 receptor activation promotes long‐term potentiation and synaptic tagging/capture in hippocampal area CA2

The FEBS Journal, EarlyView.
Activation of dopamine receptor D1 (D1R) stimulates PKA and ERK pathways via dissociation of stimulatory and olfactory G protein alpha subunits (Gαs/olf). PKA relieves striatal‐enriched protein tyrosine phosphatase (STEP) inhibition of ERK, promoting cyclic adenosine monophosphate response element‐binding protein (CREB)‐driven transcription of ...
Kevin Chua, Yee Song Chong, Sreedharan Sajikumar   +2 more
wiley   +1 more source

Off-label prescribing of antipsychotics - a questionnaire survey of Finnish physicians

, 2021
Jami Pentinlehto, Marianne Haapea, Lotta Ylitolonen, Anni‐Emilia Alakokkare, Solja Niemelä, Jouko Miettunen, Matti Penttilä, Hannu Koponen, Jussi Seppälä, Matti Isohanni, Nina Rautio, Erika Jääskeläinen   +11 more
openalex   +1 more source